Acutus Medical announces pricing of $158.8M IPO | Blood diagnostics startup Sight raises $71M | Q2 sales rise for Accelerate Diagnostics
August 7, 2020
ADVAMED SmartBrief
News for medical technology professionalsSIGN UP ⋅   SHARE
Top Story
Biocept and Aegea Biotechnologies will be working together to develop a PCR-based COVID-19 assay using Switch-Blocker technology. The deal's financial terms were not disclosed.
Full Story: GenomeWeb Daily News (free registration) (8/6) 
LinkedIn Twitter Facebook Email
Business & Market Trends
An initial public offering of more than 8.8 million shares of common stock has been priced by Acutus Medical at $18 each with the goal of raising $158.8 million. The offering, set to close Aug. 10, includes a 30-day option for underwriters to buy 1,323,529 more shares.
Full Story: BioWorld (free content) (8/6) 
LinkedIn Twitter Facebook Email
Sight Diagnostics, an Israeli startup that developed a blood analysis machine that uses machine vision, raised $71 million in its Series D round. With the new capital in hand, the company will focus on sales in the US.
Full Story: TechCrunch (tiered subscription model) (8/5) 
LinkedIn Twitter Facebook Email
Accelerate Diagnostics generated $2.1 million in revenues during its second quarter, up 17% from the same period a year earlier
Full Story: 360Dx (tiered subscription model) (8/6) 
LinkedIn Twitter Facebook Email
Science & Health
Digital breast tomography was more cost-effective than digital mammography in 66% of breast screening scenarios at a willingness-to-pay threshold of $38,500 per life-year gained and 36% of scenarios at a threshold of $22,000, according to a study in Radiology. The study found cost-effectiveness of DBT varied based on willingness-to-pay thresholds and digital mammography recall rates, researchers said.
Full Story: AuntMinnie (free registration) (8/7) 
LinkedIn Twitter Facebook Email
Emerging Technologies
Israel-based PregnanTech has created LIONESS, an implantable device that keeps the cervix elongated despite contractions and lessens the load on the cervix, helping prevent preterm birth.
Full Story: MedGadget (8/6) 
LinkedIn Twitter Facebook Email
Government & Regulatory
The FDA has given emergency use authorization to Vela Diagnostics for the manual version of its ViroKey SARS-CoV-2 RT-PCR Test.
Full Story: MassDevice (Boston) (8/6) 
LinkedIn Twitter Facebook Email
The FDA has given expanded clearance to Adaptive Biotechnologies for its clonoSEQ assay that is used to evaluate minimal residual disease in chronic lymphocytic leukemia patients. The test can now be used to monitor and detect MRD in bone marrow or blood samples.
Full Story: GenomeWeb Daily News (free registration) (8/6) 
LinkedIn Twitter Facebook Email
European regulators have given CE mark approval to DiaSorin for its Liaison Testosterone xt test that can help detect fertility disorders like hyperandrogenism and hypogonadism.
Full Story: 360Dx (tiered subscription model) (8/6) 
LinkedIn Twitter Facebook Email
AdvaMed Events and Education
Join us this fall for a new conference experience -- The Virtual MedTech Conference! We have reimagined how to bring you valuable opportunities to learn, network and connect in today's world. Expect the same high-quality education, world-class speakers and valuable business development in a dynamic and immersive virtual format. In addition, you have the unique opportunity to experience more of the conference with on demand content and partnering from Sept. 8 to Oct. 23, and livestreamed sessions taking place from October 5-7. Registration is now open -- secure your pass today. Learn more.
LinkedIn Twitter Facebook Email
With our member companies on the front lines of the fight against the COVID-19 pandemic, AdvaMed is working diligently to address the medtech industry's needs and provide resources that support you and your businesses during this challenging time. To better support you, we have launched a new COVID-19 Resource Center to provide important information to companies about the federal response to COVID-19, best practices and other valuable resources. Learn more.
LinkedIn Twitter Facebook Email
About AdvaMed | Join | Courses | Events | Newsroom
  Senior Legal Counsel
COLOPLAST CORP. - Minneapolis, MN, US
View More Listings | Post a Job
Sharing AdvaMed SmartBrief with your network keeps the quality of content high and these newsletters free.
Help Spread the Word
Or copy and share your personalized link:
There is no such thing as failure, there's just giving up too soon.
Jonas Salk,
virologist, medical researcher
LinkedIn Twitter Facebook Email
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Sign Up  |    Update Profile  |    Advertise with SmartBrief
Unsubscribe  |    Privacy policy
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004